Risikoreduktion für vertebrale Frakturen unter Denosumab bei Patienten mit normaler und osteopenischer Knochendichte

Zusammenfassung

Einleitung

Die Ergebnisse der HALT-Prostata-karzinom Studie (1) zeigten, dass Denosumab bei Prostatakarzinompatienten unter hormonablativer Therapie (HALT) die Knochenmineraldichte (BMD) gegenüber Placebo an allen Messorten signifikant erhöhte und die Inzidenz vertebraler Frakturen nach 36 Monaten signifikant um 62 % senkte. Keine Unterschiede wurden hinsichtlich der Zeit bis zur ersten klinischen Fraktur (jegliche nonvertebrale oder klinisch vertebrale Fraktur) beobachtet. In einer Post-hoc-Analyse wurde nun überprüft, ob Denosumab auch bei Patienten mit normaler bis osteopenischer Knochendichte das Risiko für neue vertebrale Frakturen reduziert.

Methoden

Hierzu wurde bei allen Teilnehmern der HALT-Studie (n = 1468) mit einem BMD-T-Score > –2,5 an Lendenwirbelsäule (LWS), Gesamthüfte und Schenkelhals sowie auswertbarem Frakturstatus die Inzidenz neuer vertebraler Frakturen nach 36 Monaten unter Behandlung mit Denosumab vs. Placebo ermittelt.

Ergebnisse

Zu Studienbeginn wiesen 1174 bzw. 80 % der Studienteilnehmer einen BMD-T Score > –2,5 an allen drei Messorten auf. 1087 bzw. 74 % der Studienteilnehmer erfüllten die Kriterien für die Frakturauswertung. In dieser Subgruppe reduzierte Denosumab das Risiko für vertebrale Frakturen nach 36 Monaten gegenüber Placebo signifikant um 61 % (Placebo: 2,8 %; Denosumab: 1,1 %; p = 0,0386). Weitere Frakturendpunkte wurden nicht untersucht.

Fazit

Denosumab reduzierte das Risiko für vertebrale Frakturen bei Patienten der HALTStudie mit normaler und osteopenischer Knochendichte in ähnlichem Ausmaß wie im Gesamtkollektiv.

Summary

Introduction

Results from the HALT Prostate Cancer Trial (1) showed that denosumab increased bone mineral density (BMD) compared with placebo in men receiving androgen deprivation therapy (ADT; bilateral orchiectomy or GnRH-agonist therapy planned for ≥ 12 months) for nonmetastatic prostate cancer at all sites measured (lumbar spine [LS], total hip, femoral neck, 1/3 distal radius, and whole body). Of note, denosumab also decreased the cumulative incidence of new vertebral fractures by 62 % at 36 months (3.9 % in the placebo group and 1.5 % in the denosumab group, relative risk, 0.38; 95 % confidence interval [CI], 0.19 to 0.78; p = 0.006). We conducted a post-hoc subgroup analysis to determine if non-osteo-porotic patients also benefit from a reduction in fracture risk. Patients from the HALT Prostate Cancer Trial (n = 1,468) were included in this subgroup analysis, if their respective lowest baseline BMD T-Score at LS, total hip, or femoral neck was > –2.5. Incidence of new vertebral fractures between the denosumab and the placebo groups was compared after 36 months for all participants of the Vertebral Fracture Analysis Subset (VFAS: participants with baseline fracture status and more than one post baseline fracture evaluation) of this subgroup.

Results

A total of 1,174 patients (80 % of all enrolled patients) had a baseline BMD T-Score > –2.5 at all three sites and 1,087 (74 % of all enrolled patients) were included in the VFAS. Patients who received denosumab had a significantly decreased incidence of new vertebral fractures at 36 months (1.1 %, vs. 2.8 % with placebo; relative risk 0.39; 95 % CI 0.15 to 0.99; p = 0.0386), which was similar to the reduction in the total HALT Prostate Cancer Trial population (relative risk, 0.38, see above). In an additional analysis excluding patients with prevalent vertebral fractures at baseline (n = 845; VFAS n = 789), fracture incidence with denosumab (3/413 or 0.7 %) was still significant lower than with placebo (10/376 or 2.7 %) in the subgroup of non-osteo-porotic men (relative risk 0.27; 95 % CI 0.08 to 0.99; p = 0.0335). When analysing fracture risk subgroups according to the major DVO (Dachverband Osteologie) criteria (age, gender, T-score, and ADT) at baseline, the risk for new vertebral fractures in the low risk subgroup (10-year fracture risk for vertebral and hip fractures ≤ 30 %) was significantly reduced with denosumab compared with placebo (denosumab: 6/577 [1.0 %]; placebo: 16/560 [2.9 %]; relative risk 0.36; 95 % CI 0.14 to 0.92; p = 0.0248). There were no significant differences in the reduction of new vertebral fractures between subgroups based on minimal BMD T-Score (normal, osteopenic, or osteo-porotic), indicating BMD-independent efficacy of denosumab.

Conclusion

In summary, denosumab increased BMD at all sites in men receiving ADT for nonmetastatic prostate cancer. In addition, a reduction in the incidence of new vertebral fractures was shown with denosumab vs. placebo. Fracture risk reduction was similar in patients with BMD in the normal to osteopenic range as seen in the entire population, even after exclusion of men with prevalent vertebral fractures. A significant reduction in fracture risk was also observed in patients at low fracture risk according to DVO guidelines.

Schlüsselwörter

Denosumab - ADT - Prostatakarzinom - Osteoporose - Frakturrisiko

Keywords

Denosumab - ADT - prostate cancer - osteoporosis - fracture risk

• Literatur

• 1 Smith MR, Egerdie B, Toriz NH. et al. Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer. N Engl J Med 2009; 361: 745-755.
• 2 Krebs in Deutschland 2007/2008. 8. Ausgabe. Robert Koch-Institut und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V., Hrsg. Berlin, 2012
• 3 Bolla M. Adjuvant hormonal treatment with radiotherapy for locally advanced prostate cancer. Eur Urol 1999; 35 (Suppl. 01) S23-S26.
• 4 Bolla M, Collette L, Blank L. et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 2002; 360: 103-108.
• 5 Messing EM, Manola J, Sarosdy M. et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341: 1781-1788.
• 6 Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms AWMFRegister-Nummer (043–022OL) Version 2.0 – 1. Aktualisierung 2011; Zugriff am 10.05.2014 unter: http://www.awmf.org/uploads/tx_szleitlinien/043–022OLl_S3_Prostatakarzinom_2011.pdf
• 7 Morote J, Orsola A, Planas J. et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol 2007; 178 (4 Pt 1): 1290-1295.
• 8 Abrahamsen B, Nielsen MF, Eskildsen P. et al. Fracture risk in Danish men with prostate cancer: a nationwide register study. BJU Int 2007; 100 (04) 749-754.
• 9 Malcolm JB, Derweesh IH, Kincade MC. et al. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer. Can J Urol 2007; 14 (03) 3551-3559.
• 10 Alibhai SMH, Duong-Hua M, Cheung AM. et al. Fracture Types and Risk Factors in Men With Prostate Cancer on Androgen Deprivation Therapy: A Matched Cohort Study of 19,079 Men. J Urol 2010; 184: 918-924.
• 11 Michaelson MD, Kaufman DS, Lee H. et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007; 25: 1038-1042.
• 12 Smith MR, Eastham J, Gleason DM. et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169: 2008-2012.
• 13 Greenspan SL, Nelson JB, Trump DL. et al. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007; 146: 416-424.
• 14 Fachinformation Prolia® . Stand Juli. 2013
• 15 Greenspan SL, Wagner J, Nelson JB. et al. Vertebral Fractures and Trabecular Microstructure in Men With Prostate Cancer on Androgen Deprivation Therapy. JBMR 2013; 28 (02) 325-332.
• 16 Sullivan S, Wagner J, Resnick NM. et al. Vertebral Fractures and the Misclassification of Osteoporosis in Men with Prostate Cancer. J Clin Densitom 2011; 14 (03) 348-353.
• 17 Dachverband Osteologie e. V. DVO-Leitlinie 2009 zur Prophylaxe, Diagnostik und Therapie der Osteoporose bei Erwachsenen – Langfassung. Osteologie 2009; 18: 304-328.
• 18 Smith MR, Saad F, Egerdie B. et al. Effects of Denosumab on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer. J Urol 2009; 182: 2670-2676.
• 19 Hadji P, Bock O, Resch H. et al. Reduktion des Frakturrisikos unter Denosumab bei postmenopausalen Frauen in Abhängigkeit der Behandlungsbedürftigkeit nach DVO-Leitlinie 2009: Eine Subgruppenanalyse der FREEDOM-Studie. Osteologie 2013; 22: 39-45.
• 20 Smith M, Egerdie B, Sieber P. et al. Overall survival in men with and without prevalent vertebral fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer. ESMO. 2009 Abstract 7005 und Präsentation..